TP0586532

a non-hydroxamate LpxC inhibitor

Also Known As:

4-((1S,5R)-6-(2-(4-(3-((2-((1S)-1-hydroxyethyl)imidazol-1-yl)methyl)-1,2-oxazol-5-yl)phenyl)ethynyl)-3-azabicyclo(3.1.0)hexan-3-yl)butanoic acid

Networked: 4 relevant articles (2 outcomes, 1 trials/studies)

1.	Infections 05/01/2022 - "Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection model." 05/01/2022 - "These results indicate the potential for TP0586532 to have clinical efficacy at reasonable doses against infections caused by carbapenem-resistant Enterobacteriaceae. " 01/01/2022 - "The estimated maximum unbound plasma concentration value at the effective dose of TP0586532 in murine infection models was around 13 μg ml-1. " 01/01/2022 - "Our study revealed that a combination therapy consisting of TP0586532 and meropenem has the potential to be a novel therapeutic option for CRE infections." 01/01/2022 - "Combination therapy consisting of TP0586532 and meropenem has potential as a treatment for CRE infections. "
2.	Sepsis (Septicemia) 01/01/2022 - "These results indicate that the inhibitory effect of TP0586532 on LPS release from pathogenic bacteria might be of benefit in patients with sepsis."
3.	Pneumonia (Pneumonitis) 01/01/2022 - "Furthermore, the effects of TP0586532 on LPS release and interleukin (IL)-6 production in the lung were determined using a murine model of pneumonia caused by K. "

1.	Therapeutics